Calcitonin
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Reduces bone breakdown and treats osteoporosis and Paget's disease.
Reported benefits
Reduced bone loss, pain relief in bone diseases
Protocols & dosing
Typical dosage: 100-200 IU (daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Calcitonin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Nasal irritation (spray form), nausea
References
No external sources have been catalogued for this article yet.
Related peptides
- Abaloparatide — Advanced bone anabolic
- BPC-157 — Bone and cartilage healing
- Collagen Peptides — Structural bone and joint support
- GHK-Cu — Bone remodeling support
- Navepegritide — PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026.
- Pentosan Polysulfate — Cartilage and joint protection
Categories: Bone & Joint